TCP
RARE icon

Tourbillon Capital Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Tourbillon Capital Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-80,000
Closed -$3.91M – 88
2014
Q1 		$3.91M Buy
+80,000
New +$4.12M 0.18% 69

Other funds holding RARE

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Tourbillon Capital Partners's RARE Position: Q2 2014 in Review

Tourbillon Capital Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2014, closing a stake of 80,000 shares — an estimated $3.91M sold.

Tourbillon Capital Partners first reported a position in RARE in Q1 2014 and held it in 1 quarter. The position peaked at $3.91M in Q1 2014. 81 funds tracked by Wall St. Rank hold RARE as of Q2 2014.

  • Tourbillon Capital Partners reported no remaining Ultragenyx Pharmaceutical position as of Q2 2014 after selling out during the quarter.
  • Tourbillon Capital Partners sold 80,000 Ultragenyx Pharmaceutical shares in Q2 2014, an estimated $3.91M.
  • Tourbillon Capital Partners first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 1 quarter.
  • Tourbillon Capital Partners's Ultragenyx Pharmaceutical position peaked at $3.91M in Q1 2014.
  • 81 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2014.

Based on Tourbillon Capital Partners's 13F filing for Q2 2014, filed 14 Aug 2014.